Voyager Therapeutics Inc. has announced a collaboration with Transition Bio to discover and develop novel small molecule therapies targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Under the agreement, Transition Bio will focus on the discovery and optimization of small molecules up to the nomination of a development candidate, after which Voyager has the option to license exclusive global rights for further development and commercialization. Transition Bio will receive an upfront payment in the single-digit millions and is eligible for milestone payments totaling up to $500 million, as well as high single-digit to low double-digit royalties on net sales. The partnership leverages Transition Bio's molecular condensate technology and Voyager's expertise in neurotherapeutics to address the challenges of targeting TDP-43 pathology in neurodegenerative diseases.